Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Microsoft
MSFT
|
+$536M |
| 2 |
Apple
AAPL
|
+$362M |
| 3 |
Micron Technology
MU
|
+$270M |
| 4 |
Eli Lilly
LLY
|
+$228M |
| 5 |
Cisco
CSCO
|
+$179M |
Top Sells
| 1 |
Broadcom
AVGO
|
+$472M |
| 2 |
Tesla
TSLA
|
+$463M |
| 3 |
NVIDIA
NVDA
|
+$424M |
| 4 |
Coinbase
COIN
|
+$236M |
| 5 |
Meta Platforms (Facebook)
META
|
+$228M |
Sector Composition
| 1 | Technology | 19.7% |
| 2 | Healthcare | 16.66% |
| 3 | Consumer Discretionary | 13.03% |
| 4 | Industrials | 9.61% |
| 5 | Financials | 9.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SRTA
2526
Strata Critical Medical, Inc. Class A Common Stock
SRTA
$351M
| $875K | ﹤0.01% |
297,700
+6,400
| +2% | +$18.8K |
|
2527
Global X SuperDividend ETF
SDIV
$964M
| $875K | ﹤0.01% |
37,171
-25,829
| -41% | -$608K |
|
2528
St. Joe Company
JOE
$3.01B
| $875K | ﹤0.01% |
+15,002
| New | +$875K |
|
2529
Meridian
MRBK
$171M
| $875K | ﹤0.01% |
69,200
+34,600
| +100% | +$437K |
|
2530
Shattuck Labs
STTK
$92M
| $875K | ﹤0.01% |
250,600
-141,410
| -36% | -$494K |
|
2531
Tile Shop Holdings
TTSH
$273M
| $870K | ﹤0.01% |
132,025
+22,025
| +20% | +$145K |
|
|
AC
2532
DELISTED
Associated Capital Group
AC
| $868K | ﹤0.01% |
24,500
-200
| -0.8% | -$7.08K |
|
2533
Adaptive Biotechnologies
ADPT
$1.92B
| $867K | ﹤0.01% |
169,400
+17,600
| +12% | +$90.1K |
|
|
GLDG
2534
GoldMining Inc
GLDG
$235M
| $867K | ﹤0.01% |
922,200
+631,000
| +217% | +$593K |
|
2535
Lowe's Companies
LOW
$152B
| $867K | ﹤0.01% |
+3,200
| New | +$867K |
|
2536
Alta Equipment Group
ALTG
$239M
| $866K | ﹤0.01% |
128,500
+41,200
| +47% | +$278K |
|
2537
SmartRent
SMRT
$273M
| $866K | ﹤0.01% |
500,600
+302,900
| +153% | +$524K |
|
|
INZY
2538
DELISTED
Inozyme Pharma
INZY
| $862K | ﹤0.01% |
164,800
-23,039
| -12% | -$120K |
|
2539
Star Holdings Shares of Beneficial Interest
STHO
$118M
| $859K | ﹤0.01% |
62,099
+31,899
| +106% | +$441K |
|
2540
Wave Life Sciences
WVE
$1.11B
| $857K | ﹤0.01% |
+104,520
| New | +$857K |
|
2541
AGF US Market Neutral Anti-Beta Fund
BTAL
$378M
| $853K | ﹤0.01% |
+43,525
| New | +$853K |
|
|
OKUR
2542
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$33.1M
| $853K | ﹤0.01% |
50,153
+5,933
| +13% | +$101K |
|
|
GOGL
2543
DELISTED
Golden Ocean Group
GOGL
| $852K | ﹤0.01% |
+63,700
| New | +$852K |
|
|
SNT
2544
Senstar Technologies
SNT
$105M
| $850K | ﹤0.01% |
534,869
-7,000
| -1% | -$11.1K |
|
2545
Community Health Systems
CYH
$412M
| $850K | ﹤0.01% |
140,093
-397,000
| -74% | -$2.41M |
|
2546
InnovAge Holding
INNV
$616M
| $849K | ﹤0.01% |
141,500
+5,100
| +4% | +$30.6K |
|
2547
Abeona Therapeutics
ABEO
$330M
| $849K | ﹤0.01% |
134,278
-369,015
| -73% | -$2.33M |
|
2548
iShares US Financials ETF
IYF
$4.08B
| $842K | ﹤0.01% |
8,100
+5,600
| +224% | +$582K |
|
2549
iShares Russell Mid-Cap ETF
IWR
$44.8B
| $837K | ﹤0.01% |
+9,500
| New | +$837K |
|
2550
Century Therapeutics
IPSC
$43.3M
| $835K | ﹤0.01% |
488,200
+322,700
| +195% | +$552K |
|